September 20, 2012 – Philadelphia Common Pleas Court Judge Arnold New has agreed to a request from Johnson and Johnson Lawyers to quash the subpoena from lawyers of a 17-year-old boy. The boy’s family is suing the company for side effects their child suffered after taking the antipsychotic drug Risperdal, made by Johnson and Johnson. This ruling, which quashes the subpoena calling for Johnson & Johnson chief executive officer Alex Gorsky cannot be called as a trial witness.

The ruling was made in connection to the Risperdal lawsuit that was brought in by 21 years old, “Aron Banks” a residence of Philadelphia. The lawsuit put-up by the plaintiff claimed that the drug caused him to grow breast tissues that compelled him to suffer huge physical and mental trauma. The plaintiff is a 21 years boy from Sherman, Texas and claims he was prescribed Risperdal during his childhood days and after taking the drug he began growing breasts when he was 12.

It is important to underline here that J&J’s Risperdal is facing lots of lawsuits from consumers who have been using it. The first one that began on Sept. 10 accuses manufacturer of not revealing unsafe aspects of the drug to common people and the plaintiff had to undergo mastectomy in which his breast tissues were suctioned out. However the manufacturer settled with the plaintiff amicably. Though the terms of the settlement were not disclosed, defendants told the case was settled and there is no pending issue associated with the case.

Risperdal is an antipsychotic drug that prescribed to treat schizophrenia, schizo affective disorder, and many other maniac diseases related to bipolar disorders.

Following its strong and acute serotonin, adrenergic and dopaminergic antagonistic behavior USFDA approved it on 1993 to treat patients who are indicated for schizophrenia and associated maniac attacks.  The drug received overwhelming response from experts and physicians so much so as on August 2007 it was the only drug approved by the USFDA to treat schizophrenic patients who are around 13-17 years old.

Jhonson & Johnson is facing a number of lawsuits and cases suits for its marketing practices related to Risperdal. As of now the manufacturer is on the verge of losing a multi-million judgment. The company is already on the negotiating table with the US Federal Government that may compel the pharmaceutical giant to lose a huge sum of $2 billion while in Texas it had already paid $158 million to avid court trial and proceedings.